Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) have received an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Rosetta Genomics’ rating score has declined by 100% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a 12 month consensus price objective of $2.05 for the company, according to Zacks. Zacks has also given Rosetta Genomics an industry rank of 114 out of 265 based on the ratings given to related companies.
Separately, Barrington Research lowered shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://weekherald.com/2017/12/26/rosetta-genomics-ltd-rosg-receives-consensus-recommendation-of-buy-from-brokerages-4.html.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.